对单克隆抗体向CEACAM5表达瘤的表皮类-类相互作用的结构见解
Anand Kumar1, Francis Duffieux2, Marie Gagnaire2
1Integrated Drug Discovery, Sanofi R&D, Paris, France.
Nature communications
|October 31, 2024
概括
图萨米他马布拉坦辛通过结合其A3-B3域来准人类CEACAM5 (hCEACAM5). 结构分析揭示了关键的表皮质 - 侧皮质相互作用,使瘤中CEACAM5的特定向成为可能.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 免疫学 免疫学 免疫学
背景情况:
- 与癌胚抗原相关的细胞粘附分子 (CEACAMs) 在各种癌症类型中经常过度表达.
- 图萨米他马布 (Tusamitamab ravtansine) 是一种抗体-药物联合体,旨在专门针对人类CEACAM5 (hCEACAM5).
研究的目的:
- 阐明tusamitamab对hCEACAM5.5的特异性的分子基础.
- 为了绘制tusamitamab和hCEACAM5.5之间精确的表位-副位相互作用的地图.
主要方法:
- 使用/交换质谱法 (HDX-MS) 来识别tusamitamab抗原结合片段 (Fab) 的帕拉托普.
- 表面等离子体共振 (SPR) 用于评估结合亲和力,并确定涉及复杂形成的关键残留物.
- 使用冷电子显微镜 (cryo-EM) 确定了hCEACAM5 A3-B3域的高分辨率结构,该域与tusamitamab Fab.
主要成果:
- 图萨米塔马布 (tusamitamab Fab) 抛物线被绘制为其重链和轻链上的特定残留物.
- 关键重链残留物 (96-108) 的氨酸替代变体废除了与hCEACAM5的结合,证实了它们的重要性.
- 冷-EM结构揭示了hCEACAM5 A3-B3域上的一个不连续的表位,包括在Asn612处的N连接的曼诺斯,与tusamitamab paratope相互作用.
结论:
- 这项研究成功地绘制了表位 - 副位接口,解释了tusamitamab对hCEACAM5.5的高特异性.
- 接口上的合规约束允许tusamitamab选择性地准hCEACAM5,使其与其他CEACAM家族成员区分开来.
- 这些发现为合理设计针对CEACAM5表达瘤的向治疗提供了结构性基础.
更多相关视频
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.2K
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.4K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Immunoglobulin-like Cell Adhesion Molecules
3.2K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.2K
Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
